Breast cancer drug Tamoxifen works best against larger, less aggressive, hormone signalling tumours

Embargoed until: Publicly released: 2021-07-01 01:00

International

CC-0

Swedish and US scientists have re-analysed the data from a previous clinical trial of the breast cancer drug Tamoxifen and say it is most effective for women who have larger tumours, less aggressive tumours, and/or tumours which are progesterone receptor–positive - a type of tumour that can receive signals from progesterone which could boost their growth.

Attachments

Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.

Research JAMA, Web page The URL will go live after the embargo ends

Journal/
conference: JAMA Network Open

Research:Paper

Organisation/s: Karolinska Institutet and University Hospital, Sweden

Funder: This work was supported by grant 2020-02466 (Dr Lindström) from the Swedish Research Council (Vetenskapsrådet); grant 2019-00477 from the Swedish Research Council for Health,Working life and Welfare (FORTE); grants 180385 (Dr Stål) and 190140Pj01H (Dr Lindström) from the Swedish Cancer Society (Cancerfonden); and funding from Gösta Milton Donation Fund (Dr Lindström).

Media Contact/s

Contact details are only visible to registered journalists.